Loading the section…

NSPR: financial statements from SEC — TradeAlmanac

NSPR

InspireMD Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	3M	3M	2M	2M	2M	2M
Cost of revenue	3M	2M	1M	1M	1M	1M
Gross profit	687,000	864,000	313,000	292,000	414,000	331,000
Research and development	5M	4M	4M	4M	4M	3M
Selling, general and administrative	5M	6M	5M	5M	3M	4M
Operating expenses	15M	14M	13M	12M	9M	9M
Operating income	−14M	−13M	−13M	−11M	−8M	−8M
Net income	−14M	−13M	−13M	−11M	−8M	−8M
Earnings per share	−0.16	−0.17	−0.26	−0.22	−0.16	−0.22
Earnings per share, diluted	−0.16	−0.17	−0.26	−0.22	−0.16	−0.22
Weighted average shares	84M	73M	51M	50M	48M	36M
Weighted average shares, diluted	84M	73M	51M	50M	48M	36M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	11M	9M	63M	12M	12M	19M	16M	28M
Short-term investments	30M	45M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−12M	−9M
Depreciation and amortisation	149,000	98,000
Share-based compensation	581,000	3M
Capital expenditure	194,000	359,000
Investing cash flow	15M	2M
Financing cash flow

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator